The Surprising Food to Eat More of If You Have Diabetes, According to a New Study
Sesame products—like oil, seeds or tahini—could support heart health when used consistently.
While promising, the evidence is lower-quality, so speak with a healthcare provider before making any major changes.Heart disease is a top health concern for good reason—it's the leading cause of death worldwide. And if you're among the 38.4 million American adults who are living with diabetes, your risk is even higher. That's because diabetes doesn't just affect blood sugar—it also contributes to a cascade of problems that raise the chances of having a heart attack or stroke. These include high levels of LDL ('bad') cholesterol, elevated triglycerides and chronic oxidative stress, which damages blood vessels over time. Finding simple, effective ways to reduce this risk is a major priority in diabetes care.
One promising approach researchers have been exploring is food—especially foods with bioactive compounds that go beyond basic nutrition. Sesame (yes, the same seed you'll find on buns and bagels) has been a key ingredient in many diets for centuries and contains powerful compounds like sesamin and sesamol that act as antioxidants and support heart and metabolic health.
Until now, studies on sesame's health benefits have been relatively small and inconsistent. But a new meta-analysis published in Diabetes & Metabolic Syndrome: Clinical Research and Reviews brings together the results of 13 clinical trials to take a closer look. The researchers focused on people with diabetes and evaluated how sesame products affected a wide range of cardiovascular risk factors, including blood sugar, cholesterol levels and markers of oxidative stress. Their findings suggest sesame may do more than add flavor—it could also play a meaningful role in protecting your heart.
Researchers conducted a systematic review and meta-analysis, a study method that pools data from multiple past trials to look for patterns. They included 13 randomized controlled trials involving a total of 731 adults with diabetes. Most participants had type 2 diabetes, and the studies were conducted across several countries, including Iran, India, Brazil and Pakistan.
Participants received sesame in various forms—such as sesame oil, whole seeds or capsules—at doses ranging from 200 to 60,000 milligrams per day. The interventions lasted between six and 12 weeks. The researchers measured outcomes like blood sugar, cholesterol, antioxidant activity, body weight and inflammation markers. They used the GRADE system, a formal framework for evaluating the strength of scientific evidence.
Overall, the study found that sesame products were linked to significant improvements in several cardiovascular disease risk factors for people with diabetes. Specifically, sesame consumption:
Lowered fasting blood glucose
Reduced hemoglobin A1c (a measure of long-term blood sugar control)
Decreased post-meal blood glucose
Reduced LDL cholesterol
Decreased total cholesterol and triglycerides
Increased levels of two key antioxidant enzymes: catalase (CAT) and superoxide dismutase (SOD)
These changes suggest that sesame may help regulate blood sugar, improve lipid profiles and protect against oxidative stress—three critical goals in managing diabetes and reducing the risk of heart disease.
However, not all findings were positive. The researchers didn't find significant improvements in HDL ('good') cholesterol, insulin resistance, inflammation markers like C-reactive protein or blood pressure. In addition, the effects appeared to diminish once sesame supplementation stopped, suggesting ongoing use may be necessary.
It's worth noting that the quality of evidence in this study was rated 'very low' due to limitations like small sample sizes, short trial durations, inconsistent results and risk of bias in study design. That means while the findings are promising, they should be interpreted with caution.
That said, sesame is a safe and nutritious ingredient to include in your diet, even if these specific heart-health benefits aren't fully confirmed. It's rich in healthy fats, fiber and antioxidants, and previous studies have linked it to lower inflammation, improved blood pressure and better cholesterol levels.
If you're living with diabetes or concerned about heart health, adding sesame products to your diet could be a simple, budget-friendly step with potential upside. In the reviewed studies, most benefits were seen with higher doses (around 30 grams per day) and longer use (eight weeks or more), so consistency matters.
Try adding sesame oil to stir-fries or salad dressings, sprinkling toasted seeds over vegetables and grains or using tahini in sauces, dips and smoothies. Crushed or blended sesame (like tahini or sesame oil) may offer more benefits than whole seeds, since grinding improves the bioavailability of beneficial compounds like sesamin.
Of course, sesame isn't a magic bullet. It should be part of a broader strategy that includes medical treatment, physical activity and a balanced diet. And if you're on medications for blood sugar or cholesterol, check with your healthcare provider before starting any supplement.
Sesame may offer heart-protective benefits for people with diabetes, according to a new meta-analysis. It helped improve blood sugar, cholesterol and antioxidant activity—three pillars of cardiovascular health. While the overall quality of the evidence is low, these findings add to a growing body of research suggesting that sesame could be a helpful addition to diabetes care. Incorporating sesame oil, tahini or seeds into your meals may be a flavorful and health-supportive choice worth exploring.
Read the original article on EATINGWELL
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
11 minutes ago
- Yahoo
US pediatric group breaks with CDC advice, recommends COVID vaccines for young children
The American Academy of Pediatrics released its vaccine recommendations on Aug. 19 in a break from federal guidance shaped by Health and Human Services Secretary Robert F. Kennedy Jr. The AAP, in tandem with multiple other professional medical associations, previously decried a May announcement made by Kennedy Jr. that the COVID-19 vaccine would no longer be included in the Centers for Disease Control's recommended immunizations for healthy children and pregnant women, a move that went against previous expert guidance and bypassed the normal scientific review process. The AAP, a professional organization of over 65,000 board-certified pediatricians dedicated to advancing children's medicine, said in a June 26 statement that it would "continue to publish its own evidence-based recommendations and schedules," as the creation of federal immunization policy is 'no longer a credible process." Kennedy Jr. drew further ire from medical communities when he fired all 17 original members of the Advisory Committee on Immunization Practices, the committee of health experts that provides guidance on vaccine use to the CDC, replacing them with members that critics have called unqualified. Some of the members, like Kennedy Jr., have a history of anti-vaccine advocacy and involvement in anti-vaccine groups. Here's what to know about the new AAP guidance and how it differs from federal guidelines. What is the AAP guidance on COVID-19 vaccines for children? The AAP schedule lists which vaccines children should get at certain ages and provides updated guidance on influenza, RSV, and COVID-19 immunizations for children and adolescents from birth to age 18. The schedule recommends that all children between six months and 23 months receive the latest COVID-19 vaccine to reduce the chance of serious illness. Children and adolescents aged 2 to 18, without other high-risk factors like immunosuppression, can receive and should be offered the vaccine if they were not previously immunized, according to the guidance. Children, teens, and adults alike who are at increased risk of serious infection should receive the vaccine if they have not already, AAP said, adding that its recommendation differed from the CDC, which it said is now staffed with people who have a history of spreading vaccine misinformation. "The AAP will continue to provide recommendations for immunizations that are rooted in science and are in the best interest of the health of infants, children, and adolescents," AAP President Dr. Susan J. Kressly, MD, said in a statement. "Pediatricians know how important routine childhood immunizations are in keeping children, families and their communities healthy and thriving." What is the federal guidance on COVID-19 vaccines for children? The CDC did not go as far as completely removing COVID-19 vaccination from its immunization schedule despite Kennedy Jr.'s insistence. Instead, the agency changed its language from recommending the vaccine annually to suggesting parents consult with their child's physician on whether to vaccinate. Kennedy Jr. previously said that the CDC planned only to recommend the COVID vaccine for people over the age of 65 and those at high personal risk of infection, though the agency's website still contains information recommending it for everyone over the age of six months. A notice on the top webpages on the topic reads, "COVID-19 vaccine recommendations have recently been updated for some populations. This page will be updated to align with the updated immunization schedule," as of Aug. 19. This change to whom the vaccine is recommended could make it harder for others who want the COVID-19 vaccine to get it, experts warned. Since insurance coverage typically follows federal recommendations, anyone who wants the shot but isn't on the CDC's recommendation list may have to pay the price out of pocket HHS Communications Director Andrew Nixon defended the decision in a statement to USA TODAY, accusing the AAP, which receives funding from pharmaceutical companies like Pfizer, of failing to have proper conflict-of-interest safeguards in place. "By bypassing the CDC's advisory process and freelancing its own recommendations, while smearing those who demand accountability, the AAP is putting commercial interests ahead of public health and politics above America's children," Nixon said. Kennedy Jr. shared a separate response on social media on Aug. 19, pointing out that the agency's top donors are four companies that "make virtually every vaccine on the CDC recommended childhood vaccine schedule" and saying that the AAP recommendations are "corporate-friendly" and may "promote commercial ambitions of AAP's Big Pharma benefactors" instead of public health. "AAP should also be candid with doctors and hospitals that recommendations that diverge from the CDC's official list are not shielded from liability under the 1986 Vaccine Injury Act," his post concluded. USA TODAY reached out to AAP for comment on Aug. 19 but has not received a response. The new Advisory Committee on Immunization Practices didn't vote on COVID-19 vaccine recommendations when they met in June and are expected to reconvene in "September/October," according to the CDC. The FDA has signaled intentions to revoke the Pfizer COVID-19 shot for young, healthy children. In early August, HHS announced that it would pull $500M in funding from mRNA vaccine research and development. This article originally appeared on USA TODAY: Young kids should receive COVID vaccine despite CDC advice: AAP Solve the daily Crossword
Yahoo
41 minutes ago
- Yahoo
XtalPi Signs MOU with Dong-A ST for Joint Research and Development of Immunology and Inflammation Therapies
CAMBRIDGE, Mass., Aug. 19, 2025 /PRNewswire/ -- XtalPi announced on the 20th that it signed a Memorandum of Understanding (MOU) with Korea's leading pharmaceutical company Dong-A ST, to jointly develop therapeutics for immunological and inflammatory diseases. This collaboration will be based on XtalPi's intelligent and automated drug discovery platform, which integrates artificial intelligence (AI), quantum physics, and large-scale automated robotic experiments. The two companies plan to co-identify targets and discover first-in-class or best-in-class drug candidates using XtalPi's proprietary AI-driven drug discovery platform. The XtalPi platform combines the speed and generative power of AI with the accuracy of its robotic lab-in-the-loop to accelerate drug discovery and vastly expand the explorable chemical space. This integrated workflow spans deep-learning-based molecule design, quantum physics and molecular dynamics simulations for predicting drug-target interactions, automated chemical synthesis, and experimental validation of candidate compounds' key pharmaceutical properties. Leveraging its expertise in immunology and inflammation as well as its experience in small molecule drug development, Dong-A ST will actively participate throughout the entire R&D process—including candidate validation, efficacy and safety testing, and the formulation of preclinical and clinical development strategies. The company also plans to explore strategies for pipeline expansion and assess commercialization potential. Through this partnership, Dong-A ST aims to strengthen its pipeline in the immunology and inflammation space and expand its R&D scope beyond small molecule therapeutics into areas such as targeted protein degradation (TPD), biologics, antibody-drug conjugates (ADC), and gene therapies. John Wang, Senior Vice President of Drug Discovery at XtalPi, stated: "The combination of Dong-A ST's extensive expertise and XtalPi's proven AI-robotics platform is well-positioned to translate scientific innovation into competitive precision medicines. Together, we aim to rapidly discover and rigorously validate novel drug candidates across multiple modalities to unlock unique market opportunities, and deliver transformative therapies for global patients." Jae-Hong Park, Head of R&D at Dong-A ST, remarked, "This collaboration marks a pivotal step in expanding Dong-A ST's R&D capabilities," adding, "By leveraging synergies with XtalPi's AI platform, we expect to accelerate the development of next-generation treatments for immune and inflammatory diseases." Meanwhile, both Dong-A ST and XtalPi operate open innovation offices in Boston, USA. This geographic proximity will facilitate closer and more efficient collaboration throughout the drug discovery process. About Dong-A ST Dong-A ST Co., Ltd. ( was established in 1932 and is a leading Korean pharmaceutical company engaged in the development, manufacturing, and commercialization of ethical drugs, biosimilars, medical devices, and diagnostics. Its key products include Stillen (gastritis), Zydena (erectile dysfunction), Motilitone (functional dyspepsia), and Imuldosa (ustekinuma biosimilar). Leveraging strong R&D capabilities and a history of innovation, Dong-A ST is expanding its pipeline in immunology, inflammation, neurological disease, metabolic diseases, and oncology, while advancing into new modalities such as biologics, ADCs, TPD, and gene therapies. About XtalPi XtalPi Holdings Limited (XtalPi, was founded in 2015 by three physicists from the Massachusetts Institute of Technology (MIT). It is an innovative R&D platform powered by quantum physics, artificial intelligence, and robotics. By integrating first-principles calculations, AI algorithms, high-performance cloud computing, and standardized automation systems, XtalPi provides digital and intelligent R&D solutions for companies in the pharmaceutical, materials science, agricultural technology, energy, new chemicals, and cosmetics industries. View original content to download multimedia: SOURCE XtalPi Inc. Sign in to access your portfolio

CNN
42 minutes ago
- CNN
FDA warns against eating certain shrimp sold at Walmart amid investigation into radioactive contamination
Federal agencies Food & healthFacebookTweetLink Follow The US Food and Drug Administration on Tuesday urged the public not to eat certain bags of frozen raw shrimp sold at Walmart, citing concerns about unsanitary conditions and radioactive contamination found in shipments from the same supplier. The FDA said that a radioactive isotope, cesium-137, was detected in a sample of breaded shrimp detained at US ports – in Los Angeles, Houston, Savannah, and Miami – from an Indonesian supplier named BMS Foods. Those contaminated shipments never reached the US market. However, because Walmart's raw frozen shrimp came from the same supplier – and the agency said it 'appears to have been prepared, packed, or held under insanitary conditions whereby it may have become contaminated with Cs-137' – officials advised consumers to avoid eating them. The levels of cesium detected – about 68 becquerels per kilogram – were well below the FDA's intervention level of 1,200 Bq/kg. Still, regulators issued the advisory out of caution, citing the potential risks of cancer from long-term, low-dose exposure and problems at the supplier's facility. The advisory applies to 2-pound Great Value bags of white vannamei shrimp, all carrying a best-by date of March 15, 2027. They were distributed to Walmart stores in at least 13 states: Alabama, Arkansas, Florida, Georgia, Kentucky, Louisiana, Missouri, Mississippi, Ohio, Oklahoma, Pennsylvania, Texas and West Virginia. The agency is advising consumers who purchased the shrimp to throw it away or return it, and, said an investigation is ongoing in conjunction with Indonesian seafood regulatory authorities. Walmart confirmed to CNN that it 'immediately recalled the product from impacted stores.' CNN has also reached out to the supplier for comment.



